Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Jemperli

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    - PMLiVE

    GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

    The deal includes a PDE3/4 inhibitor in clinical development for COPD

    - PMLiVE

    MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

    More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

    The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

    - PMLiVE

    GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

    More than 50,000 cases of the blood cancer are diagnosed in Europe each year

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

    Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

    EU flag

    EC approves SpringWorks Therapeutics’ Ezmekly to treat rare genetic disorder NF1

    Neurofibromatosis type 1 affects an estimated 135,000 people in the EU

    EU flag

    EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

    The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020

    EU flag

    EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

    An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links